Literature DB >> 9477183

Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.

N Miyanaga1, H Akaza, S Kameyama, T Hachiya, S Ozono, M Kuroda, H Koga, K Koiso.   

Abstract

BACKGROUND: The BTA test is a latex agglutination assay for the qualitative detection in the urine of analytes that are associated with bladder tumor. We compared the results of the BTA test with those of voided urine cytology (VUC) in patients with bladder cancer.
METHODS: A multicenter trial was performed at 6 institutions. A total of 132 patients with histologically diagnosed bladder cancer were enrolled. Urine samples were split for BTA and VUC testing.
RESULTS: The sensitivities of the BTA test and VUC were 57.6% and 37.9%, respectively; this difference was significant (P < 0.001). The BTA test had much higher sensitivity for small, solitary, superficial tumors than did VUC.
CONCLUSION: The BTA test is simple to perform, gives rapid results, and is far more sensitive than VUC for detection of bladder cancer. The BTA test has the potential to become an additional tool for detecting bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9477183     DOI: 10.1111/j.1442-2042.1997.tb00308.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  3 in total

1.  Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.

Authors:  D Chao; S J Freedland; A J Pantuck; A Zisman; A S Belldegrun
Journal:  Rev Urol       Date:  2001

2.  Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients.

Authors:  M Takashi; U Schenck; K Kissel; H Leyh; U Treiber
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

3.  Urinary laminin-γ2 is a novel biomarker of non-muscle invasive urothelial carcinoma.

Authors:  Masayuki Kamada; Naohiko Koshikawa; Tomoko Minegishi; Chiaki Kawada; Takashi Karashima; Taro Shuin; Motoharu Seiki
Journal:  Cancer Sci       Date:  2015-11-06       Impact factor: 6.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.